-
Je něco špatně v tomto záznamu ?
Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats
H. Sutovska, L. Molcan, M. Majzunova, M. Sykora, L. Kopkan, M. Zeman
Jazyk angličtina Země Irsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- albuminurie MeSH
- aldosteron * farmakologie MeSH
- antagonisté mineralokortikoidních receptorů farmakologie MeSH
- geneticky modifikovaná zvířata MeSH
- hypertenze * MeSH
- krevní tlak MeSH
- krysa rodu rattus MeSH
- ledviny MeSH
- receptory mineralokortikoidů genetika MeSH
- spironolakton farmakologie MeSH
- voda farmakologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Aldosterone regulates blood pressure (BP) through water and sodium balance. In our study, we studied if continuous treatment with a mineralocorticoid receptor antagonist, spironolactone (30 mg/kg/day) for 20 days can: 1) attenuate hypertension development and restore inverted 24-h BP rhythm in hypertensive transgenic (mRen-2)27 rats (TGR) measured by telemetry; 2) improve function of the kidneys and heart; 3) be protective against high salt load (1% in water) by mitigating oxidative injury and improving kidney function. Spironolactone decreased albuminuria and 8-isoprostane in normal and salt load conditions in BP-independent effects. Salt load increased BP, impaired autonomic balance, suppressed plasma aldosterone level and increased natriuresis, albuminuria and oxidative injury in TGR. Spironolactone did not restore the inverted 24-h rhythm of BP in TGR, therefore, mineralocorticoids are not crucial in regulation of BP daily profile. Spironolactone improved kidney function, decreased oxidative stress and was protective against high salt load in the BP-independent manner.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010852
- 003
- CZ-PrNML
- 005
- 20230801132644.0
- 007
- ta
- 008
- 230718s2023 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.mce.2023.111967 $2 doi
- 035 __
- $a (PubMed)37210027
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Sutovska, Hana $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic. Electronic address: hana.sutovska@uniba.sk
- 245 10
- $a Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats / $c H. Sutovska, L. Molcan, M. Majzunova, M. Sykora, L. Kopkan, M. Zeman
- 520 9_
- $a Aldosterone regulates blood pressure (BP) through water and sodium balance. In our study, we studied if continuous treatment with a mineralocorticoid receptor antagonist, spironolactone (30 mg/kg/day) for 20 days can: 1) attenuate hypertension development and restore inverted 24-h BP rhythm in hypertensive transgenic (mRen-2)27 rats (TGR) measured by telemetry; 2) improve function of the kidneys and heart; 3) be protective against high salt load (1% in water) by mitigating oxidative injury and improving kidney function. Spironolactone decreased albuminuria and 8-isoprostane in normal and salt load conditions in BP-independent effects. Salt load increased BP, impaired autonomic balance, suppressed plasma aldosterone level and increased natriuresis, albuminuria and oxidative injury in TGR. Spironolactone did not restore the inverted 24-h rhythm of BP in TGR, therefore, mineralocorticoids are not crucial in regulation of BP daily profile. Spironolactone improved kidney function, decreased oxidative stress and was protective against high salt load in the BP-independent manner.
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní tlak $7 D001794
- 650 12
- $a aldosteron $x farmakologie $7 D000450
- 650 _2
- $a receptory mineralokortikoidů $x genetika $7 D018161
- 650 _2
- $a spironolakton $x farmakologie $7 D013148
- 650 _2
- $a albuminurie $7 D000419
- 650 12
- $a hypertenze $7 D006973
- 650 _2
- $a ledviny $7 D007668
- 650 _2
- $a geneticky modifikovaná zvířata $7 D030801
- 650 _2
- $a voda $x farmakologie $7 D014867
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x farmakologie $7 D000451
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Molcan, Lubos $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic. Electronic address: lubos.molcan@uniba.sk
- 700 1_
- $a Majzunova, Miroslava $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic. Electronic address: miroslava.majzunova@uniba.sk
- 700 1_
- $a Sykora, Matus $u Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovak Republic. Electronic address: matus.sykora@savba.sk
- 700 1_
- $a Kopkan, Libor $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Electronic address: libor.kopkan@img.cas.cz
- 700 1_
- $a Zeman, Michal $u Department of Animal Physiology and Ethology, Faculty of Natural Sciences, Comenius University, Bratislava, Slovak Republic. Electronic address: michal.zeman@uniba.sk
- 773 0_
- $w MED00003387 $t Molecular and cellular endocrinology $x 1872-8057 $g Roč. 572, č. - (2023), s. 111967
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37210027 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132640 $b ABA008
- 999 __
- $a ok $b bmc $g 1963332 $s 1197117
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 572 $c - $d 111967 $e 20230518 $i 1872-8057 $m Molecular and cellular endocrinology $n Mol Cell Endocrinol $x MED00003387
- LZP __
- $a Pubmed-20230718
